Three new glycopeptide antibiotics, aridicins A, B, and C, produced by Kibdelosporangium aridum have a spectrum of antimicrobial activity in vitro which is similar to that of vancomycin. The antimicrobial activities of these glycopeptides against clinical bacterial isolates were compared with those of vancomycin and other related glycopeptide antibiotics in vitro by agar dilution and microtiter broth dilution tests and in vivo in mouse protection studies. In vitro they were somewhat less effective than vancomycin against strains of Staphylococcus aureus and less active against coagulase-negative Staphylococcus spp. However, they were more active than vancomycin against strains of Streptococcus faecalis and markedly superior to vancomycin and other glycopeptide antibiotics against strains of Clostridium difficile. In experimental infections, aridicin A was effective against strains of S. aureus, S. epidermidis, Streptococcus faecalis, and Streptococcus pyogenes, although its 50% effective doses were higher than those of vancomycin when administered after infection. After subcutaneous administration, aridicin A had a higher peak level in serum and a longer half-life than vancomycin or teicoplanin. The aridicins were markedly superior to vancomycin when administered prior to infection in mouse protection tests, indicating long-acting potential.
Aridicins are glycopeptide antibiotics of the vancomycin class which are produced by a new genus of the order Actinomycetales, Kibdelosporangiium aridum ATCC 39922. The production, isolation, spectrum of activity, and chemical characterization of these antibiotics have been reported previously (8, 9) . These glycopeptides differ from most members of this class, with the exception of teicoplanin (1) . Both the aridicins and teicoplanin (teichomycin) possess a glycolipid constituent and have an acidic isoelectric point. The spectrum of antimicrobial activity in vitro for all of the glycopeptides reported in the literature is similar to that of vancomycin and is limited, probably owing to their molecular size, to gram-positive bacteria (10) (11) (12) . The microbiological and pharmacokinetic properties of the aridicins were compared with those of vancomycin and other members of this class of antibiotics. NT"b NT ANTIMICROB. AGENTS CHEMOTHER. 'ED50 is the total dose. The 95% confidence limits are given in parentheses.
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that of vancomycin against the strains tested. Aridicin A and vancomycin also protected when given as a single dose 1 h after infection. Aridicin A was compared with vancomycin in determinations of prophylactic protective activity against S. aureus HH127 (Table 4 ). Aridicin A gave good protection when administered as early as 18 h before infection. Vancomycin failed to protect when administered 6 or 18 h before infection under the same conditions. Pharmacokinetics in mice. The serum profile of aridicin A was compared with those of vancomycin and teicoplanin in mice. The peak concentration in serum and the apparent t1/2P
(beta elimination time) were 84 ,ug/ml and 243 min for aridicin A, 19 p.g/ml and 26 min for vancomycin, and 56 ,ug/ml and 116 min for teicoplanin. Aridicin A had a higher peak concentration (>4-and 1.5-fold) and longer half-life (nine-and twofold) in serum than vancomycin and teicoplanin, respectively.
The potential for increased clinical utility of glycopeptide antibiotics has been recognized in recent years with the growing need for vancomycin for treatment of methicillinresistant staphylococci, surgical prophylaxis, prophylaxis for cancer patients on immunosuppressive therapy, and treatment of enterocolitis due to C. difficile (3, 5, 6) . Our interest in the discovery of new glycopeptides with antimicrobial and pharmacokinetic advantages over vancomycin led to the isolation of the aridicins. The aridicins are less active than vancomycin and teicoplanin against staphylococci, particularly the coagulase-negative staphylococci. In common with teicoplanin (7), they are more active against enterococci. The aridicins are the most active glycopeptides against C. difficile. The increased concentrations in serum and extended half-life of aridicin A over those of teicoplanin as well as vancomycin indicate good potential for once-a-day administration and prophylactic use.
The aridicins and teicoplanin share two physicochemical characteristics which distinguish them from other members of the vancomycin class. The contribution of the glycolipid constituents and the acidic isoelectric point to the microbiological and pharmacokinetic differences described are the subject of further investigations.
